Midostaurin (rydapt0) for some types of acute myeloid leukaemia - Improved survival, but adverse effects underestimated

首页> 外文期刊>Prescrire international >Midostaurin (rydapt0) for some types of acute myeloid leukaemia - Improved survival, but adverse effects underestimated

【24h】

Midostaurin (rydapt0) for some types of acute myeloid leukaemia - Improved survival, but adverse effects underestimated

机译：米多司他林（rydapt0）治疗某些类型的急性髓系白血病 - 生存率提高，但不良反应被低估

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The standard treatment for patients with acute myeloid leukaemia is a combination of daunorubicin + cytarabine as induction therapy, followed by consolidation therapy with chemotherapy or bone marrow transplantation, Maintenance therapy has not been shown to be of benefit in prolonging survival. About one-third of patients have tumour cells carrying a mutation in the FLT3 gene, which is an adverse prognostic factor. Midostaurin (Rydapt, Novartis) is an inhibitor of multiple tyrosine kinases, including the FLT3 kinase. It has been authorised in the European Union for patients with newly diagnosed acute myeloid leukaemia who carry a FLT3 mutation.

机译：急性髓系白血病患者的标准治疗是柔红霉素+阿糖胞苷联合诱导治疗，然后进行巩固治疗与化疗或骨髓移植，维持治疗尚未证明对延长生存期有益。大约三分之一的患者的肿瘤细胞携带 FLT3 基因突变，这是一个不良预后因素。Midostaurin （Rydapt， Novartis）是多种酪氨酸激酶的抑制剂，包括 FLT3 激酶。它已在欧盟获准用于携带 FLT3 突变的新诊断急性髓系白血病患者。

著录项

来源
《Prescrire international》 |2019年第201期|40-41|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类药学;
关键词

相似文献

外文文献
中文文献

1. Differential expression of terminal transferase (TdT) in acute lymphocytic leukaemia expressing myeloid antigens and TdT positive acute myeloid leukaemia as compared to myeloid antigen negative acute lymphocytic leukaemia [J] . Elisabeth Paietta, Janis Racevskis, John M. BennettPeter H. Wiernik british journal of haematology . 1993,第3期

机译：Differential expression of terminal transferase (TdT) in acute lymphocytic leukaemia expressing myeloid antigens and TdT positive acute myeloid leukaemia as compared to myeloid antigen negative acute lymphocytic leukaemia
2. Adverse effects of aneuploidy on the outcome of remission induction therapy for acute nonlymphocytic leukaemia: analysis of types of treatment failure [J] . H. D. Preisler, Peter A. Reese, SMichelle J. MarinelloLillian Pothier british journal of haematology . 1983,第3期

机译：Adverse effects of aneuploidy on the outcome of remission induction therapy for acute nonlymphocytic leukaemia: analysis of types of treatment failure
3. Five year leukaemia‐free survival of 72 and 77 for early stage acute and chronic myeloid leukaemia treated by HLA‐identical sibling bone marrow transplantation [J] . K. Atkinson, K. Downs, A. DoddsA. ConcannonS. Milliken Australian and New Zealand journal of medicine . 1996,第1期

机译：Five year leukaemia‐free survival of 72 and 77 for early stage acute and chronic myeloid leukaemia treated by HLA‐identical sibling bone marrow transplantation
4. Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: A matched-pair analysis [O] . Ishiyama, Ken, Takami, Akiyoshi, Kanda, Yoshinobu, 2012

机译：allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis

Midostaurin (rydapt0) for some types of acute myeloid leukaemia - Improved survival, but adverse effects underestimated

摘要

著录项

相似文献

相关主题

期刊订阅